Rituximab biosimilars: introduction into clinical practice

被引：2
|
作者：
Makita, Shinichi [1 ]
Tobinai, Kensei [1 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Chuo Ku, Tokyo 1040045, Japan
来源：
LANCET HAEMATOLOGY | 2017年 / 4卷 / 08期
关键词：
LYMPHOMA;
D O I：
10.1016/S2352-3026(17)30124-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E342 / E343
页数：2
相关论文
共 50 条
  • [11] Rituximab biosimilars for lymphoma in Europe
    Jurczak, Wojciech
    Danecka, Monika Dlugosz
    Buske, Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 1045 - 1056
  • [12] Biosimilars Have Arrived: Rituximab
    Greenwald, Maria
    Tesser, John
    Sewell, K. Lea
    ARTHRITIS, 2018,
  • [13] Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars
    Diaz, Luis Perez
    Millan, Susana
    Chaban, Nuran
    Campo, Ana del
    Spitzer, Eduardo
    FUTURE ONCOLOGY, 2021, 17 (19) : 2529 - 2544
  • [14] Biosimilars 101: considerations for US oncologists in clinical practice
    Camacho, Luis H.
    Frost, Craig P.
    Abella, Esteban
    Morrow, Phuong K.
    Whittaker, Sadie
    CANCER MEDICINE, 2014, 3 (04): : 889 - 899
  • [15] Biologicals and Biosimilars in Hematology: The Case of Rituximab
    Vulto, Arnold G.
    HEMASPHERE, 2019, 3 (06):
  • [16] Rituximab: Experience in routine clinical practice
    Thomas, J.
    Lapraik, C. J.
    Rant, D.
    Somerville, M.
    Scott, D. G. I.
    RHEUMATOLOGY, 2006, 45 : I47 - I47
  • [17] Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
    Minyoung Jang
    Steven Simoens
    Taeksang Kwon
    BioDrugs, 2021, 35 : 89 - 101
  • [18] Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
    Jang, Minyoung
    Simoens, Steven
    Kwon, Taeksang
    BIODRUGS, 2021, 35 (01) : 89 - 101
  • [19] Introduction and commentary: Biosimilars-clinical trial and safety considerations
    Reinisch, Walter
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 44 (06) : S1 - S1
  • [20] Introduction and Commentary: Paving the Way for Biosimilars in Oncology, Part 3 Clinical and Economic Impact of Oncology Biosimilars
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2014, 41 (02) : S1 - S2
12345